Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27006592
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Cancer+Growth+Metastasis
2016 ; 9
(ä): 1-8
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Impact of Transfusion on Cancer Growth and Outcome
#MMPMID27006592
Goubran HA
; Elemary M
; Radosevich M
; Seghatchian J
; El-Ekiaby M
; Burnouf T
Cancer Growth Metastasis
2016[]; 9
(ä): 1-8
PMID27006592
show ga
For many years, transfusion of allogeneic red blood cells, platelet concentrates,
and plasma units has been part of the standard therapeutic arsenal used along the
surgical and nonsurgical treatment of patients with malignancies. Although the
benefits of these blood products are not a matter of debate in specific
pathological conditions associated with life-threatening low blood cell counts or
bleeding, increasing clinical evidence is nevertheless suggesting that deliberate
transfusion of these blood components may actually lead to negative clinical
outcomes by affecting patient's immune defense, stimulating tumor growth,
tethering, and dissemination. Rigorous preclinical and clinical studies are
needed to dimension the clinical relevance, benefits, and risks of transfusion of
blood components in cancer patients and understand the amplitude of problems.
There is also a need to consider validating preparation methods of blood
components for so far ignored biological markers, such as microparticles and
biological response modifiers. Meanwhile, blood component transfusions should be
regarded as a personalized medicine, taking into careful consideration the status
and specificities of the patient, rather than as a routine hospital procedure.
free
free
free
